ASTRAZEN financials

Chart ›

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast closeFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
15,593————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
448448536506500
15,145————
2,2762,2761,7161,2961,003
—+32.6%+32.5%+29.2%—
262262254184165
11.5%11.5%14.8%14.2%16.5%
233233214170149
18818811616299.3
8.2%8.2%6.7%12.5%9.9%
₹75.01₹75.01₹46.30₹64.60₹39.72
—+62.0%−28.3%+62.7%—
−15.1−15.165.492.558.3
−3.6−3.6−1.8−10.8−8.5
−18.8−18.863.681.849.8
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ASTRAZEN₹6,237.00

ASTRAZEN

₹ CroreMcap ₹15,593 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current
last close
Market Capitalization————15,592.5
- Cash, Equiv & ST Investments500.3505.6536.1447.7447.7
Enterprise Value————15,144.8
Revenue1,003.01,295.51,716.32,275.62,275.6
Growth %, YoY—+29.2+32.5+32.6—
EBITDA165.1184.4254.0262.0262.0
Margin %16.4614.2414.8011.5111.51
EBIT148.9169.5214.0233.5233.5
Net Income99.3161.5115.7187.5187.5
Margin %9.9012.476.748.248.24
EPS, Adj (current shares)39.7264.6046.3075.0175.01
Growth %, YoY—+62.7-28.3+62.0—
Cash from Operations58.392.565.4-15.1-15.1
Capital Expenditures-8.5-10.8-1.8-3.6-3.6
Free Cash Flow49.881.863.6-18.8-18.8
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

AstraZeneca Pharma India financials and key ratios

Figures from the company's filings with NSE

In FY26 its consolidated net profit was ₹188 crore on revenue of ₹2,276 crore. It had no borrowings on 31 March 2026. Promoters held 75.00% of the shares on 30 September 2026.

Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

AstraZeneca Pharma India at a glance · consolidated

ROE (FY26)
22.8%+7.2 pts vs FY25ROCE 25.6%
Debt to equity
0.00net cash ₹449 Cr
Promoter holding
75.00%unchanged vs 30 Jun 202630 September 2026
Net worth
₹873 Cr31 March 2026
Free cash flow (FY26)
−₹18.8 Cr
EPS (FY26)
₹75.01

Questions

Is AstraZeneca Pharma India debt free?

Yes. AstraZeneca Pharma India had no borrowings on 31 March 2026 (consolidated balance sheet), and it held ₹449 crore of cash, bank balances and current investments.

What is the AstraZeneca Pharma India debt to equity ratio?

AstraZeneca Pharma India's debt-to-equity ratio was 0.00 on 31 March 2026: no borrowings against total equity of ₹873 crore.

What is the AstraZeneca Pharma India dividend in 2026 and its record date?

In 2026, AstraZeneca Pharma India has declared one dividend: ₹36 with record date 31 July 2026.

What is the AstraZeneca Pharma India net worth?

AstraZeneca Pharma India's net worth — shareholders' equity in its consolidated balance sheet — was ₹873 crore on 31 March 2026.

What is the AstraZeneca Pharma India book value per share?

AstraZeneca Pharma India's book value per share was ₹349.12 on 31 March 2026: shareholders' equity of ₹873 crore divided by the 2.5 crore shares in issue.

What is the AstraZeneca Pharma India promoter holding?

Promoters held 75.00% of AstraZeneca Pharma India on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.

What is the AstraZeneca Pharma India ROE and ROCE?

In FY26, AstraZeneca Pharma India's return on equity (ROE) was 22.8% and its return on capital employed (ROCE) was 25.6%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 15.6% and ROCE 27.9%.

What is the AstraZeneca Pharma India shareholding pattern?

On 30 September 2026, AstraZeneca Pharma India's shares were held by promoters 75.00%, foreign portfolio investors (FII/FPI) 2.64%, domestic institutions (DII) 7.09% (including mutual funds at 7.01%) and retail and other non-institutional investors 15.27%. Over the year, FII holding was down 0.10 percentage points from 2.74% and DII holding was up 1.83 percentage points from 5.26%.

What is the AstraZeneca Pharma India free cash flow?

In FY26, AstraZeneca Pharma India generated ₹15.1 crore of cash from operations and spent ₹3.6 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹18.8 crore. In FY25 it was ₹63.6 crore.

What is the AstraZeneca Pharma India EPS?

AstraZeneca Pharma India's basic earnings per share (EPS) were ₹75.01 in FY26, against ₹46.30 in FY25.

What is the AstraZeneca Pharma India revenue and profit in FY26?

In FY26 (April 2025–March 2026), AstraZeneca Pharma India's consolidated net profit was ₹188 crore, up 62.0% from ₹116 crore in FY25, on revenue from operations of ₹2,276 crore (up 32.6%). Over three years, from FY23, net profit was up 88.9%.

Where do these AstraZeneca Pharma India figures come from?

From AstraZeneca Pharma India's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.